Coral Omene, MD, PhD

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

Collecting comprehensive patient data, including social determinants of health, is crucial for equitable value-based cancer care, yet administrative burdens could worsen existing disparities, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

Defining "value" in cancer care goes beyond survival and should encompass patient quality of life metrics, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

Insurance hurdles in value-based cancer care create delays and anxiety for patients and providers, complicating access to essential treatments, explained Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.